general-medicine
IMDC (Heng) Score for Metastatic RCC
International Metastatic RCC Database Consortium criteria for systemic-therapy-treated mRCC (Heng 2009). Sums 6 adverse factors. Predicts overall survival on first-line therapy and stratifies for combination therapy decisions.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Crizanlizumab · P-selectin Inhibitor — Sickle Cell Disease
- Voxelotor · Haemoglobin S Polymerisation Inhibitor — Sickle Cell Disease
- Mosunetuzumab · CD20×CD3 Bispecific T-Cell Engager
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.